Evaluation of Bispecific Antibodies in NHPs

In recent years, bispecific antibodies (BsAbs) have emerged as a novel strategy in tumor immunotherapy. BsAbs combine two distinct antigen targets within a single antibody molecule, potentially enhancing clinical efficacy and safety. As a result of this dual targeting approach, the clinical therapeutic effects of BsAbs are considered superior to those of monoclonal antibodies.

WuXi AppTec scientists showcase a case study evaluating the PK/PD/safety profile of a BsAb that targets both CD3 and Claudin18.2 (CLDN18.2). BsAbs that target both CD3 and CLDN18.2 bind to both CD3-expressing T cells and CLDN18.2-expressing tumor cells. This crosslinking activates T cells and causes them to lyse the tumor cells.

Evaluation of Bispecific Antibodies in NHPs

Download